Related references
Note: Only part of the references are listed.Phase III Open-Label Randomized Study of Eribulin Mesylate Versus Capecitabine in Patients With Locally Advanced or Metastatic Breast Cancer Previously Treated With an Anthracycline and a Taxane
Peter A. Kaufman et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
ESO-ESMO 2nd international consensus guidelines for advanced breast cancer (ABC2)
F. Cardoso et al.
ANNALS OF ONCOLOGY (2014)
Efficacy of eribulin in women with metastatic breast cancer: a pooled analysis of two phase 3 studies
Chris Twelves et al.
BREAST CANCER RESEARCH AND TREATMENT (2014)
Chemotherapy and Targeted Therapy for Women With Human Epidermal Growth Factor Receptor 2-Negative (or unknown) Advanced Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline
Ann H. Partridge et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
US Food and Drug Administration Approval Overview in Metastatic Breast Cancer
Patricia Cortazar et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Overall Survival As the Outcome for Randomized Clinical Trials With Effective Subsequent Therapies
Edward L. Korn et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Eribulin monotherapy versus treatment of physician's choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised study
Javier Cortes et al.
LANCET (2011)
Evaluation of tumor response, disease control, progression-free survival, and time to progression as potential surrogate end points in metastatic breast cancer
Tomasz Burzykowski et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Breast cancer with synchronous metastases: Trends in survival during a 14-year period
F Andre et al.
JOURNAL OF CLINICAL ONCOLOGY (2004)
Share Paper
